Nilsine Partners LLC Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Nilsine Partners LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,006 shares of the biopharmaceutical company’s stock after acquiring an additional 27 shares during the period. Nilsine Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $717,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. State Street Corp lifted its holdings in Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after acquiring an additional 11,499 shares during the last quarter. Swiss National Bank increased its holdings in Regeneron Pharmaceuticals by 0.6% in the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 301,508 shares of the biopharmaceutical company’s stock valued at $316,957,000 after purchasing an additional 3,866 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Finally, Oppenheimer decreased their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,004.57.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $686.33 on Wednesday. The firm’s 50 day simple moving average is $725.65 and its 200-day simple moving average is $933.22. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20. The firm has a market cap of $75.42 billion, a PE ratio of 16.98, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.